Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation therapy.
Autor: | Noda Y; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, White 270, Boston, MA, 02114, USA.; Department of Radiology, Gifu University, 1-1 Yanagido, Gifu, 501-1194, Japan., Pisuchpen N; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, White 270, Boston, MA, 02114, USA.; Department of Radiology, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand., Mercaldo ND; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, White 270, Boston, MA, 02114, USA., Sekigami Y; Department of Surgery, Massachusetts General Hospital, Boston, MA, 02114, USA., Michelakos T; Department of Surgery, Massachusetts General Hospital, Boston, MA, 02114, USA., Parakh A; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, White 270, Boston, MA, 02114, USA., Wo JY; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114-2696, USA., Qadan M; Department of Surgery, Massachusetts General Hospital, Boston, MA, 02114, USA., Ferrone C; Department of Surgery, Massachusetts General Hospital, Boston, MA, 02114, USA., Lillemoe KD; Department of Surgery, Massachusetts General Hospital, Boston, MA, 02114, USA., Ryan DP; Department of Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114-2696, USA., Clark JW; Department of Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114-2696, USA., Fernandez-Del Castillo C; Department of Surgery, Massachusetts General Hospital, Boston, MA, 02114, USA., Hong TS; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114-2696, USA., Kambadakone AR; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, White 270, Boston, MA, 02114, USA. akambadakone@mgh.harvard.edu. |
---|---|
Jazyk: | angličtina |
Zdroj: | European radiology [Eur Radiol] 2022 Apr; Vol. 32 (4), pp. 2470-2480. Date of Electronic Publication: 2021 Oct 19. |
DOI: | 10.1007/s00330-021-08304-y |
Abstrakt: | Objectives: To derive a CT-based scoring system incorporating arterial involvement and resectability status to predict R0 resection in patients with pancreatic ductal adenocarcinoma (PDAC) undergoing neoadjuvant chemoradiation therapy (CRT). Methods: This retrospective study included 112 patients with PDAC who underwent dynamic contrast-enhanced CT before and after neoadjuvant CRT. A 5-point score was used to determine arterial involvement (A score; 1 = no involvement, 2 = haziness, 3 = abutment, 4 = encasement, 5 = deformity) and 4-point score evaluating resectability status (R score; 1 = resectable, 2 = borderline resectable [BR] with venous involvement, 3 = BR with arterial involvement, 4 = locally advanced [LA]). A score before and after CRT were summed with R score before and after CRT to compute the AR score (AR Results: The AR Conclusions: A composite score which incorporates degree of arterial involvement and resectability status before and after neoadjuvant CRT is associated with R0 resection and discriminates between R0 and R1 resections in PDAC. Key Points: • A scoring system incorporating arterial involvement and resectability status was associated with R0 resection. • AR (© 2021. European Society of Radiology.) |
Databáze: | MEDLINE |
Externí odkaz: |